In addition, inhibition of FOXM1 function by a cell-penetrating ARF (26–44) peptide has also been revealed to lead to reduced tumour cell proliferation and angiogenesis in hepatocellular carcinoma [34], exhibiting the potential of inhibitors for FOXM1 in becoming new anticancer therapeutics. This evidence concerns the gene CDKN2A and hepatocellular carcinoma.